Literature DB >> 4824675

Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.

J Constantinidis, J Siegfried, T L Frigyesi, R Tissot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4824675     DOI： 10.1007/bf01245332

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  12 in total

1.  Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase.

Authors:  G Bartholini; W P Burkard; A Pletscher
Journal:  Nature       Date:  1967-08-19       Impact factor: 49.962

2.  [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].

Authors:  W Birkmayer; M Mentasti
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1967-08-08

3.  [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].

Authors:  J Siegfried; R Klaiber; E Perret; W H Ziegler
Journal:  Dtsch Med Wochenschr       Date:  1969-12-26       Impact factor: 0.628

4.  Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase.

Authors:  G Bartholini; J Constantinidis; R Tissot; A Pletscher
Journal:  Biochem Pharmacol       Date:  1971-06       Impact factor: 5.858

5.  [Biopsies during stereotaxic operations in Parkinson's syndrome].

Authors:  T Riechert; M A Gisinger; E Mölbert
Journal:  Neurochirurgia (Stuttg)       Date:  1967-05

6.  [The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].

Authors:  J Constantinidis; G Bartholini; F Geissbühler; R Tissot
Journal:  Experientia       Date:  1970-04-15

7.  [Two years experience with L-DOPA in association with a decarboxylase inhibitor].

Authors:  J Siegfried
Journal:  Rev Neurol (Paris)       Date:  1970-04       Impact factor: 2.607

8.  [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].

Authors:  G Gauthier; J de Ajuriaguerra; B Simona; J Constantinidis; J J Eisenring; M Krassoievitch; G Yanniotis; R Tissot
Journal:  Rev Neurol (Paris)       Date:  1970-11       Impact factor: 2.607

9.  [Selective concentration of dopamine in the parenchyma of the rat brain].

Authors:  J Constantinidis; G Bartholini; R Tissot; A Pletscher
Journal:  Helv Physiol Pharmacol Acta       Date:  1967

10.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
View more
  2 in total

Review 1.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.

Authors:  U K Rinne; E Birket-Smith; E Dupont; E Hansen; M Hyyppä; R Marttila; B Mikkelsen; H Pakkenberg; J Presthus
Journal:  J Neurol       Date:  1975-12-02       Impact factor: 4.849
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.